Ba71V-93 Antibody

What is the Ba71V-93 antibody and what viral protein does it target?

The Ba71V-93 antibody is a mouse monoclonal antibody that specifically targets the phosphoprotein p30 (also known as CP204L) of African Swine Fever Virus. This protein is a structural component of ASFV with a molecular weight of approximately 23,555 Da . The antibody is commonly generated using recombinant p30 protein (1-204AA) as the immunogen and is available in IgG1 isotype format . Methodologically, researchers should note that this antibody specifically recognizes epitopes on p30, a membrane phosphoprotein that potentially plays regulatory roles in viral signal transduction pathways .

What are the primary applications for Ba71V-93 antibody in ASFV research?

The Ba71V-93 antibody has been validated primarily for Enzyme-Linked Immunosorbent Assay (ELISA) applications . This makes it particularly useful for:

• Detection of ASFV p30 antigen in experimental samples

• Development of diagnostic assays for ASFV detection

• Screening studies examining viral load in experimental settings

• Evaluation of antibody responses in vaccine studies

When designing experiments, researchers should consider using this antibody in blocking ELISA (bELISA) formats, which have been specifically validated for examining antibody kinetics during ASFV infection .

How should Ba71V-93 antibody be stored and handled for optimal performance?

For maintaining antibody stability and activity, the Ba71V-93 antibody should be stored at -20°C or -80°C upon receipt . The antibody is typically provided in a storage buffer containing 0.03% Proclin 300, 50% glycerol, and 0.01M PBS at pH 7.4 . Methodologically important, researchers should avoid repeated freeze-thaw cycles that can degrade antibody performance . For laboratory protocols, researchers should determine optimal working dilutions empirically for each specific application, as different experimental systems may require adjustments to standard protocols.

How can Ba71V-93 antibody be used in the development of blocking ELISA for ASFV research?

Blocking ELISA (bELISA) applications using Ba71V-93 antibody involve a methodological approach where:

• Plates are coated with recombinant p30 antigen (typically in range of 1-2 μg/ml)

• Test sera are added to allow binding of any anti-p30 antibodies present in samples

• Biotinylated Ba71V-93 antibody is added, which will be "blocked" from binding if sample antibodies are present

• Detection systems (typically streptavidin-HRP) are used to quantify binding

This approach has been validated for evaluating antibody kinetics during ASFV infection, with research showing that monitoring blocking percentages provides sensitive detection of anti-ASFV responses . When designing such assays, optimization of antigen coating concentration is critical, as shown in experimental data where different concentrations of p30 protein were tested to determine optimal coating amounts (Figure 1C in reference 2).

What are the key considerations when using the Ba71V-93 antibody in immunofluorescence assays for ASFV research?

When designing immunofluorescence assays (IFA) using Ba71V-93 antibody:

• Cell fixation protocols: Optimal results have been achieved using 80% acetone fixation for 15 minutes at room temperature

• Blocking conditions: 2% BSA in PBS for 1 hour at 37°C has been shown to minimize background

• Antibody dilution: Starting dilutions of 1:20 to 1:40 are recommended for initial optimization

• Secondary antibody selection: Fluorescently-conjugated anti-mouse IgG antibodies (typically CF594 or similar fluorophores) provide optimal visualization

When evaluating results, researchers should examine subcellular localization patterns. In transfected cells expressing p30, the protein typically shows both cytoplasmic and membrane-associated distribution patterns. Control experiments using cells transfected with plasmids expressing either N-terminal or C-terminal fragments of p30 can help verify antibody specificity, as demonstrated in previous research (Figure 2A in reference 2) .

How does the Ba71V-93 antibody perform in detecting different ASFV genotypes?

The Ba71V-93 antibody recognizes p30 (CP204L), which is a highly conserved structural protein across ASFV genotypes. Methodologically, researchers should note:

• The antibody was raised against p30 from the BA71V strain (an attenuated variant of BA71)

• Cross-reactivity studies have shown recognition of p30 across multiple ASFV genotypes, including genotype I strains (BA71, E75) and genotype II strains (such as Georgia 2007/1)

• When analyzing samples from field isolates or experimental infections with different genotypes, preliminary validation using positive controls from the specific genotype is recommended

In experimental designs requiring genotype differentiation, researchers should consider using this antibody in combination with genotype-specific molecular assays for comprehensive characterization .

How can the Ba71V-93 antibody contribute to research on ASFV vaccine development, particularly regarding the BA71ΔCD2 attenuated strain?

The Ba71V-93 antibody provides valuable tools for vaccine development research involving attenuated ASFV strains like BA71ΔCD2. Methodological approaches include:

• Monitoring viral protein expression in recombinant virus production

• Assessing antigenic integrity of p30 in attenuated viral strains

• Evaluating antibody responses induced by vaccination

Research with BA71ΔCD2 (a CD2v gene deletion mutant) has demonstrated successful attenuation and protective immunity against both homologous and heterologous ASFV challenges . When designing experiments:

• Use the antibody to confirm p30 expression in cell culture systems producing BA71ΔCD2

• Employ ELISA-based assays to quantify the kinetics of anti-p30 antibody responses post-vaccination

• Consider developing competition assays to differentiate between vaccine-induced and challenge virus-induced antibody responses

The antibody can be particularly useful in studying the cross-protection mechanisms observed with BA71ΔCD2, which has shown the ability to protect against heterologous ASFV strains including E75 and Georgia 2007/1 .

What approaches can be used to correlate Ba71V-93 antibody-based assay results with cellular immune responses in ASFV vaccine studies?

Advanced research designs correlating Ba71V-93 antibody-based assays with cellular immunity should consider:

• Combined analysis of humoral responses (via p30 ELISA) and cellular responses using:

  • IFN-γ ELISPOT assays to enumerate ASFV-specific T cells

  • CFSE proliferation assays to measure antigen-specific T cell expansion

Experimental data from BA71ΔCD2 studies demonstrated that protection correlated with the presence of CD8+ T cells capable of recognizing both homologous and heterologous ASFV strains . A comprehensive methodological approach would include:

• Collecting paired serum and PBMC samples at multiple timepoints post-vaccination

• Using Ba71V-93 in ELISA to quantify anti-p30 antibody responses

• Performing CFSE proliferation assays with virus-stimulated PBMCs, followed by flow cytometry to identify CD8+ T cell responses

• Correlating antibody levels with T cell response magnitudes and protection outcomes

Research has shown that BA71ΔCD2 induces CD8+ T cells that proliferate in response to both BA71 and E75 virus stimulation (9-39% range), suggesting broad cellular immunity that contributes to cross-protection .

How can researchers address potential data inconsistencies between Ba71V-93 antibody detection and protection outcomes in ASFV challenge models?

When analyzing inconsistencies between antibody detection and protection outcomes:

• Recognize that antibody levels alone may not predict protection

• Implement multiparametric analysis approaches:

  • Measure antibody titers using standardized ELISA protocols

  • Assess antibody functionality through neutralization or inhibition assays

  • Evaluate cellular immunity markers alongside antibody responses

  • Monitor viremia using qPCR following challenge

Experimental evidence from BA71ΔCD2 vaccine studies revealed that some protected animals showed undetectable antibody levels before challenge, while some unprotected animals had high antibody titers . A methodological framework for addressing these inconsistencies includes:

This integrated approach enables correlation analysis between multiple immune parameters and protection, providing deeper insights into protective mechanisms beyond simple antibody presence .

What are the methodological considerations for using Ba71V-93 antibody in comparative studies between virulent BA71 and attenuated BA71V strains?

Advanced comparative studies between virulent BA71 and attenuated BA71V require rigorous methodological considerations:

• Genomic context: BA71V has undergone significant genomic changes during adaptation to Vero cells, including:

  • Four major deletions affecting virulence genes

  • The smallest genome among attenuated ASFV strains (170,101 bp compared to BA71's 180,365 bp)

• Protein detection strategy:

  • When using Ba71V-93 antibody, researchers should verify that epitope regions in p30 remain conserved between strains

  • Western blot analysis should be performed under both reducing and non-reducing conditions to detect potential conformational differences

  • Immunoprecipitation followed by mass spectrometry can confirm identity and post-translational modifications of p30 in different strains

• Experimental design for comparative studies:

  • Use paired samples from both BA71 and BA71V infections

  • Include appropriate controls for each strain

  • Normalize protein loading based on multiple housekeeping proteins

  • Consider temporal differences in protein expression between virulent and attenuated strains

This approach enables meaningful comparison of p30 expression patterns and immunogenicity between the virulent BA71 strain, which causes acute ASF with 100% mortality, and the attenuated BA71V strain, which produces asymptomatic infection and fails to induce protective immunity .

What are the recommended protocols for optimizing ELISA systems using Ba71V-93 antibody for ASFV research?

For optimizing ELISA systems with Ba71V-93 antibody, researchers should follow this methodological framework:

• Antigen coating optimization:

  • Test serial dilutions of recombinant p30 protein (typically ranging from 0.1-10 μg/ml)

  • Evaluate different coating buffers (carbonate buffer pH 9.6 versus PBS pH 7.4)

  • Determine optimal coating temperature and duration (4°C overnight versus 37°C for 2 hours)

• Blocking conditions optimization:

  • Compare efficiency of different blocking agents (BSA, milk powder, commercial blockers)

  • Test blocking duration (1-3 hours) and temperature (room temperature versus 37°C)

• Antibody dilution determination:

  • Create a dilution series of Ba71V-93 antibody to establish optimal working concentration

  • Evaluate signal-to-noise ratio across the dilution range

  • Verify specificity using appropriate positive and negative controls

• Detection system selection:

  • For direct detection: HRP-conjugated secondary antibodies

  • For amplified sensitivity: Biotin-streptavidin systems

  • For specialized applications: Fluorescent or chemiluminescent detection systems

This approach has been validated in studies developing p30-based diagnostic ELISAs, where careful optimization of each parameter led to improved assay performance .

What controls and validation approaches should be included when using Ba71V-93 antibody in experimental studies?

Rigorous control and validation strategies for Ba71V-93 antibody include:

• Essential controls:

  • Positive control: Samples from confirmed ASFV-infected animals or recombinant p30 protein

  • Negative control: Samples from verified ASFV-free animals

  • Isotype control: Irrelevant mouse IgG1 antibody to identify non-specific binding

  • Secondary antibody control: Omitting primary antibody to detect non-specific secondary binding

• Cross-reactivity assessment:

  • Test against other porcine pathogens (Classical Swine Fever Virus, Porcine Reproductive and Respiratory Syndrome Virus)

  • Evaluate potential cross-reactivity with porcine cellular proteins

• Assay validation metrics:

  • Sensitivity and specificity determination using characterized sample panels

  • Intra-assay and inter-assay coefficient of variation calculation

  • Limit of detection determination

  • Reproducibility assessment across different laboratories

This comprehensive validation approach ensures reliable research outcomes and facilitates comparison between different studies, as demonstrated in previous ASFV diagnostic development work .

How might Ba71V-93 antibody contribute to next-generation ASFV vaccines beyond the BA71ΔCD2 attenuated strain?

The Ba71V-93 antibody could facilitate development of next-generation ASFV vaccines through:

• Subunit vaccine development:

  • Identifying immunodominant epitopes within p30 recognized by Ba71V-93

  • Evaluating recombinant p30 constructs as potential subunit vaccine candidates

  • Monitoring antibody responses to p30 in different vaccine formulations

• Vector-based vaccine platforms:

  • Confirming expression of p30 in viral vector systems (adenovirus, modified vaccinia Ankara)

  • Assessing proper folding and presentation of p30 epitopes in vectored vaccines

  • Comparing p30-specific responses between live attenuated and vectored approaches

• Rational vaccine design:

  • Using epitope mapping with Ba71V-93 to inform structure-based vaccine design

  • Developing prime-boost strategies incorporating p30 alongside other ASFV immunogens

  • Creating DIVA (Differentiating Infected from Vaccinated Animals) compatible assays

Building on the success of BA71ΔCD2, which demonstrated cross-protection against heterologous ASFV strains, these approaches could address safety concerns while maintaining protective efficacy .

What are the potential applications of Ba71V-93 antibody in developing improved diagnostic platforms for ASFV surveillance?

Advanced diagnostic applications for Ba71V-93 antibody include:

• Multiplex detection systems:

  • Integration into bead-based multiplex assays targeting multiple ASFV proteins simultaneously

  • Development of microarray-based detection platforms for high-throughput screening

  • Creation of multiplexed lateral flow devices for field-applicable diagnostics

• Advanced immunoassay formats:

  • Time-resolved fluorescence immunoassays for enhanced sensitivity

  • Electrochemiluminescence-based detection systems

  • Proximity ligation assays for ultrasensitive p30 detection

• Point-of-care testing innovations:

  • Adaptation to smartphone-based reader systems

  • Integration with portable biosensor platforms

  • Development of isothermal amplification-linked immunoassays

These applications would build upon existing blocking ELISA platforms using Ba71V-93, which have already demonstrated efficacy in monitoring antibody responses during ASFV infection .